Causal associations of Sjögren’s syndrome with cancers: a two-sample Mendelian randomization study

Table 4 The results of horizontal pleiotropy analysis for SS on cancers

Cancer types	Horizontal pleiotropy test			MR-PRESSO
Cancer types	Intercept	SE	P value	P value	DT P value
Overall breast cancer	0.0033	0.0094	0.7377	< 1E-04	0.5067
Luminal A-like breast cancer	0.0005	0.0186	0.9780	0.0040	0.1094
Luminal B/HER2-positive-like breast cancer	0.0231	0.0321	0.4903	0.0753	NE
Luminal B/HER2-negative-like breast cancer	0.0180	0.0214	0.4225	0.3752	NE
HER2-enriched-like breast cancer	0.0124	0.0199	0.5486	0.5845	NE
Triple-negative breast cancer	0.0034	0.0338	0.9225	0.5711	NE
Overall lung cancer	− 0.0001	0.0296	0.9978	0.1498	NE
Lung adenocarcinoma	− 0.0055	0.0386	0.8908	0.4194	NE
Squamous cell lung cancer	− 0.0597	0.0556	0.3148	0.1794	NE
Prostate cancer	0.0010	0.0004	0.0338	0.1589	NE
Endometrial cancer	0.0218	0.0090	0.0360	0.1111	NE
Lymphomas	− 0.0002	0.0001	0.2323	0.0147	0.5515
Liver and bile duct cancer	− 1.93E − 06	3.84E − 05	0.9612	0.9197	NE
Cancer of urinary tract	− 4.29E − 05	0.0001	0.7207	0.1300	NE
Thyroid cancer	− 0.0953	0.1195	0.4517	0.3302	NE
Oral cavity and pharyngeal cancer	− 0.0625	0.0460	0.2111	0.0179	0.0153

Abbreviations: DT distortion test, MR-PRESSO Mendelian randomization pleiotropy residual sum and outlie, NE not estimate, SE standard error, SS Sjögren’s syndrome

ISSN: 1478-6362